Traduction de «2008 annual report and form » (Néerlandais → Français) :

Further information, including assumptions used in determining the valuation of this investment as of December 31, 2008, is provided in the 2008 Annual Report and Form 20-F under “Critical Accounting Policies and Estimates”.
D’autres informations, comprenant les hypothèses utilisées pour déterminer la valeur de cet investissement au 31 décembre 2008, figurent dans le Rapport annuel 2008 et dans le formulaire 20 F sous «Critical Accounting Policies and Estimates» (Normes comptables et estimations importantes).

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K. # # # # #
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K.

The following non-exhaustive list relating to some cases reported in the 2008 Annual Report and includes information as of the 2008 fourth quarter:
Non exhaustive, la liste suivante passe en revue quelques-uns des cas cités dans le Rapport annuel 2008 et contient les informations disponibles au quatrième trimestre 2008.

These condensed consolidated financial statements for the three-month quarterly and the 12-month periods ended December 31, 2008, were prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” and accounting policies set out in the 2008 Annual Report published on January 28, 2009.
Les comptes consolidés simplifiés pour le trimestre et la période de douze mois se terminant le 31 décembre 2008 ont été établis conformément à la norme comptable internationale 34 concernant l’information financière intermédiaire (IAS 34 « Interim Financial Reporting ») et aux normes comptables décrites dans le rapport annuel 2008 publié le 28 janvier 2009.

The principal accounting policies of Novartis are set out in note 1 to the consolidated financial statements in the 2008 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par Novartis sont exposées dans l’annexe 1 aux comptes consolidés du Groupe figurant dans le Rapport annuel 2008 et satisfont aux normes International Financial Reporting Standards (IFRS).

In particular, as discussed in notes 9 and 10 of the 2008 Annual Report, Novartis regularly reviews long-lived intangible and tangible assets, including identifiable intangible assets and goodwill for impairment.
En particulier, comme l’expliquent les annexes 9 et 10 du Rapport annuel 2008, Novartis examine régulièrement les immobilisations corporelles et incorporelles à durée d’utilité indéterminée, notamment les immobilisations incorporelles identifiables et le goodwill susceptibles de subir une perte de valeur.

As also discussed in notes 9 and 10 of the 2008 Annual Report, other intangible assets and investments in associated companies are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value.
Comme le notent également les annexes 9 et 10 du Rapport annuel 2008, les autres immobilisations incorporelles et investissements dans des sociétés associées font l’objet d’un test de dépréciation dès lors qu’un événement ou une décision les concernant suscitent des doutes quant à leur valeur inscrite au bilan.

Key assumptions and sensitivity analysis information are provided in note 10 to the Group’s consolidated financial statements in the 2008 Annual Report.
Des informations sur les hypothèses-clés et l’analyse de sensibilité sont fournies dans l’annexe 10 des comptes consolidés du Groupe figurant dans le Rapport annuel 2008.

This report “The Federal Agency for Medicines and Health Products – 2008 in words and images. Annual Report 2008” was created under the coordination of the Communication Division of the FAMHP.
This report “The Federal Agency for Medicines and Health Products – 2008 in words and images. Annual Report 2008” was created under the coordination of the Communication Division of the FAMHP.